Monoclonal Antibodies as Prophylactic and Therapeutic Agents Against Chikungunya Virus.
Where this comes from
- Record sourced from PubMed, PMID 27920182.
- Also identified by PMC identifier 5853615.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that is responsible for considerable epidemics worldwide and recently emerged in the Americas in 2013. CHIKV may cause long-lasting arthralgia after acute infection. With currently no licensed vaccines or antivirals, the design of effective therapies to prevent or treat CHIKV infection is of utmost importance and will be facilitated by increased understanding of the dynamics of chikungunya. In this article, monoclonal antibodies against CHIKV as viable prophylactic and therapeutic agents will be discussed.
Medical subject headings
- Antibodies, Monoclonal
- Antibodies, Viral
- Chikungunya Fever
- Chikungunya virus